Summary
Cell therapy offers promising opportunities to approach several diseases for which no effective therapies are currently available. However, the prognosis of the treatment efficacy commonly only relies on the progression of the disease symptoms. There is a need of tools to evaluate and predict the safety and success of cell-based treatments in earlier stages. The current lack of methods providing real-time tracking of transplanted cells and knowledge on their early biodistribution and viability, is one of the major weakness of the available cell-based treatments.
The main goal of nTRACK is to develop a safe and highly sensitive multimodal nanoimaging agent enabling noninvasive, quantitative and longitudinal stem cell tracking and whole body biodistribution. nTRACK will also provide information on cell (long-term) viability using the combination of CT, MRI and PET, which are imaging modalities that are clinically available. The synthesis of nTRACK NPs and cellular labeling processes will be scaled up and will follow good manufacturing practice (GMP) requirements. A second goal is to establish a predictive model for early assessment of treatment effectiveness, based on short-term evaluation of the typical migration and biodistribution patterns of the stem cells. This predictive model could substantially improve overall management of the disease and will transform cell therapy treatment from “one size fits all’ concept towards personalised treatment.
The nTRACK technology will be demonstrated on a muscular injury sheep model, using imaging infrastructure commonly used in hospital settings. In addition, non-clinical safety studies on the nTRACK nanoparticles will be conducted following the conclusions of a series of formal interactions with regulatory authorities, to allow the prompt introduction into clinical trials after the end of the project.
The main goal of nTRACK is to develop a safe and highly sensitive multimodal nanoimaging agent enabling noninvasive, quantitative and longitudinal stem cell tracking and whole body biodistribution. nTRACK will also provide information on cell (long-term) viability using the combination of CT, MRI and PET, which are imaging modalities that are clinically available. The synthesis of nTRACK NPs and cellular labeling processes will be scaled up and will follow good manufacturing practice (GMP) requirements. A second goal is to establish a predictive model for early assessment of treatment effectiveness, based on short-term evaluation of the typical migration and biodistribution patterns of the stem cells. This predictive model could substantially improve overall management of the disease and will transform cell therapy treatment from “one size fits all’ concept towards personalised treatment.
The nTRACK technology will be demonstrated on a muscular injury sheep model, using imaging infrastructure commonly used in hospital settings. In addition, non-clinical safety studies on the nTRACK nanoparticles will be conducted following the conclusions of a series of formal interactions with regulatory authorities, to allow the prompt introduction into clinical trials after the end of the project.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/761031 |
| Start date: | 01-10-2017 |
| End date: | 31-03-2022 |
| Total budget - Public funding: | 6 907 615,00 Euro - 6 863 864,00 Euro |
Cordis data
Original description
Cell therapy offers promising opportunities to approach several diseases for which no effective therapies are currently available. However, the prognosis of the treatment efficacy commonly only relies on the progression of the disease symptoms. There is a need of tools to evaluate and predict the safety and success of cell-based treatments in earlier stages. The current lack of methods providing real-time tracking of transplanted cells and knowledge on their early biodistribution and viability, is one of the major weakness of the available cell-based treatments.The main goal of nTRACK is to develop a safe and highly sensitive multimodal nanoimaging agent enabling noninvasive, quantitative and longitudinal stem cell tracking and whole body biodistribution. nTRACK will also provide information on cell (long-term) viability using the combination of CT, MRI and PET, which are imaging modalities that are clinically available. The synthesis of nTRACK NPs and cellular labeling processes will be scaled up and will follow good manufacturing practice (GMP) requirements. A second goal is to establish a predictive model for early assessment of treatment effectiveness, based on short-term evaluation of the typical migration and biodistribution patterns of the stem cells. This predictive model could substantially improve overall management of the disease and will transform cell therapy treatment from “one size fits all’ concept towards personalised treatment.
The nTRACK technology will be demonstrated on a muscular injury sheep model, using imaging infrastructure commonly used in hospital settings. In addition, non-clinical safety studies on the nTRACK nanoparticles will be conducted following the conclusions of a series of formal interactions with regulatory authorities, to allow the prompt introduction into clinical trials after the end of the project.
Status
CLOSEDCall topic
NMBP-15-2017Update Date
26-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
H2020-EU.2.1.2. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies
Search
Organisations
-
| LEITAT (Coördinator)
-
| "NATIONAL CENTER FOR SCIENTIFIC RESEARCH ""DEMOKRITOS"""
-
| ASPHALION SL
-
| BAR ILAN UNIVERSITY
-
| BIOEMISSION TECHNOLOGY SOLUTIONS IKE
-
| CAMBRIDGE NANOMATERIALS TECHNOLOGY LTD
-
| FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA
-
| MYBIOTECH GMBH
-
| PLURISTEM LTD
-
| RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU
-
| UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAET MAINZ
-
| VIVOTECNIA RESEARCH SL